Covid-19: EU states to resume AstraZeneca vaccine rollout
The EU's leading states are to restart their roll-out of the Oxford-AstraZeneca Covid-19 vaccine after Europe's medicine...
AstraZeneca’s Covid-19 vaccine is safe and effective and should be deployed widely, including in countries where the South African variant of the coronavirus may reduce its efficacy, a World Health Organisation panel said on Wednesday. In interim recommendations on the shot, the Strategic Advisory Group of Experts on Immunisation (SAGE) panel said the vaccine should be given in two doses with an interval of 8 to 12 weeks, and should also be used in people aged 65 and older. Even in countries such as South Africa, where questions have been raised about the AstraZeneca vaccine’s efficacy against a newly-emerged variant of the SARS-CoV-2 coronavirus, “there is no reason not to recommend its useâ€, SAGE’s chair, Alejandro Cravioto, told a briefing.“We have made a recommendation that even if there is a reduction in the possibility of this vaccine having a full impact in its protection capacity, especially against severe disease, there is no reason not to recommend its use even in countries that have circulation of the variant,†he said
This notice has been removed
The content is no longer available
AstraZeneca’s Covid-19 vaccine is safe and effective and should be deployed widely, including in countries where the South African variant of the coronavirus may reduce its efficacy, a World Health Organisation panel said on Wednesday. In interim recommendations on the shot, the Strategic Advisory Group of Experts on Immunisation (SAGE) panel said the vaccine should be given in two doses with an interval of 8 to 12 weeks, and should also be used in people aged 65 and older. Even in countries such as South Africa, where questions have been raised about the AstraZeneca vaccine’s efficacy against a newly-emerged variant of the SARS-CoV-2 coronavirus, “there is no reason not to recommend its useâ€, SAGE’s chair, Alejandro Cravioto, told a briefing.“We have made a recommendation that even if there is a reduction in the possibility of this vaccine having a full impact in its protection capacity, especially against severe disease, there is no reason not to recommend its use even in countries that have circulation of the variant,†he said
No results found
Try a different search term
Something went wrong
No notices yet
No notices match these filters
Couldn't load notices
You're all caught up 🎉
Sign in to continue to Global Noticeboard
Enter your email to receive a reset link
Create a new password for your account
You are marking this Notice are inappropriate, and you belive it infringes on the Global Noticeboard Community Guidelines (link). Is this so?
Create 3 Noticeboards to earn this Silver level Community Champion Badge.
View all badges that you can earnPlease tell us why you are reporting this content.
Discussion (0)
No comments yet